Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Launched by ASTRAZENECA · Mar 23, 2009

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult male and female patients aged 40 with stable moderate to severe COPD (GOLD guidelines).
• • Post-salbutamol (FEV1) \< 80% and ≥ 30% of predicted normal value and Post-salbutamol FEV1/FVC \< 70%.
• • Current or ex smokers of 10 pack-years.
• Exclusion Criteria:
• • Patients with no history or current diagnosis of asthma.
• • No evidence of an exacerbation within 6 weeks prior to the screening visit.
• • No evidence of clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities.
• • No contraindication to use of anticholinergic drugs such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.